NYSEMKT: APUS
Apimeds Pharmaceuticals Us Inc Stock Ownership - Who owns Apimeds Pharmaceuticals Us?

Insider buying vs selling

Have Apimeds Pharmaceuticals Us Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Christopher KimChairman and CMO2025-05-147,730$1.86
$14.38kBuy
Christopher KimChairman and CMO2025-05-1319,770$1.82
$35.98kBuy
Inscobee Inc10% Owner2025-05-1271,090$2.60
$184.83kBuy
Inscobee Inc10% Owner2025-05-1244,041$2.60
$114.51kBuy
Inscobee Inc10% Owner2025-05-1271,090$2.60
$184.83kBuy
Inscobee Inc10% Owner2025-05-1244,041$2.60
$114.51kBuy
Inscobee Inc10% Owner2025-05-12500,000$4.00
$2.00MBuy
Jakap KooDirector2025-05-1228,500$1.99
$56.72kBuy
Inscobee Inc10% Owner2025-05-12182,002$2.60
$473.21kBuy

1 of 1

APUS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when APUS insiders and whales buy or sell their stock.

APUS Shareholders

What type of owners hold Apimeds Pharmaceuticals Us Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Inscobee Inc48.54%5,619,232$9.65MInsider
Erik C. Emerson6.48%750,000$1.29MInsider
Jakap Koo5.56%643,885$1.11MInsider
Christopher Kim2.40%277,500$476.75kInsider

1 of 1

APUS vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APUS0.00%62.98%Net BuyingNet Buying
DRRX8.62%91.38%
GELS1.11%0.00%
SCYX29.75%22.73%Net BuyingNet Buying
RMTI16.14%83.86%Net BuyingNet Buying

Apimeds Pharmaceuticals Us Stock Ownership FAQ

Who owns Apimeds Pharmaceuticals Us?

Apimeds Pharmaceuticals Us (NYSEMKT: APUS) is owned by 0.00% institutional shareholders, 62.98% Apimeds Pharmaceuticals Us insiders, and 37.02% retail investors. Inscobee Inc is the largest individual Apimeds Pharmaceuticals Us shareholder, owning 5.62M shares representing 48.54% of the company. Inscobee Inc's Apimeds Pharmaceuticals Us shares are currently valued at $10.00M.

If you're new to stock investing, here's how to buy Apimeds Pharmaceuticals Us stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.